Table 1 Baseline characteristics of patients with unifocal and Multifocal NF-PNETs

Number of tumors, median

1.0 [1.0;1.0]

4.0[3.0;4.0]

1.0 [1.0;1.0]

Bifocal

-

4 (22.2%)

-

More than 2

-

14 (77.8%)

-

Male: Female

82:87

(48.5%:51.5%)

7:11

(38.9%:61.1%)

89:98

(47.6%:52.4%)

BMI (kg/m²), mean

24.2 ± 3.3

22.3 ± 3.4

24.0 ± 3.3

ASA score

I

34 (20.1%)

7 (38.9%)

41 (21.9%)

II

100 (59.2%)

8 (44.4%)

108 (57.8%)

III

35 (20.7%)

3 (16.7%)

38 (20.3%)

Sporadic vs. hereditary PNET

Sporadic

163 (96.4%)

9 (50.0%)

172 (92.0%)

MEN1

4 (2.4%)

6 (33.3%)

10 (5.3%)

VHL

2 (1.2%)

3 (16.7%)

5 (2.7%)

Tumor location

Head

61 (36.1%)

2 (11.1%)

63 (33.7%)

Body

47 (27.8%)

2 (11.1%)

49 (26.2%)

Tail

53 (31.4%)

7 (38.9%)

60 (32.1%)

Diffuse

8 (4.7%)

7 (38.9%)

15 (8.0%)

Minimally invasive approach

105 (62.1%)

11 (61.1%)

116 (62.0%)

Type of surgery

Enucleation

24 (14.2%)

0 (0.0%)

24 (12.8%)

Distal pancreatectomy

84 (49.7%)

9 (50.0%)

93 (49.7%)

Central pancreatectomy

8 (4.7%)

1 (5.6%)

9 (4.8%)

PPPD

46 (27.2%)

2 (11.1%)

48 (25.7%)

Total pancreatectomy

7 (4.1%)

6 (33.3%)

13 (7.0%)

WHO grade

Grade 1

128 (75.7%)

12 (66.7%)

140 (74.9%)

Grade 2

38 (22.5%)

5 (27.8%)

43 (23.0%)

Grade 3

3 (1.8%)

1 (5.6%)

4 (2.1%)

Largest tumor size (cm), mean

2.5 ± 2.0

2.8 ± 2.2

2.6 ± 2.0

Lymph node metastasis

16 (9.5%)

5 (27.8%)

21 (11.2%)

Distant metastasis

2 (1.2%)

1 (5.6%)

3 (1.6%)

AJCC 8th stage

Stage 1

73 (43.2%)

6 (33.3%)

79 (42.2%)

Stage 2

78 (46.2%)

7 (38.9%)

85 (45.5%)

Stage 3

15 (8.9%)

4 (22.2%)

19 (10.2%)

Stage 4

3 (1.8%)

1 (5.6%)

4 (2.1%)